Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERACITY: Sabizabulin in mCRPC
NCT04844749Phase 3Terminated
- Sponsor
- Veru Inc.
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sabizabulin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Veru Inc.. Started Jun 2021; status: terminated.
02
Drugs
sabizabulin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04844749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844749.